首页 > 最新文献

Journal of Stroke最新文献

英文 中文
Endovascular Treatment for Acute Posterior Circulation Tandem Lesions: Insights From the BASILAR and PERSIST Registries. 急性后循环串联病变的血管内治疗:来自BASILAR和PERSIST登记处的见解。
IF 6 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-31 DOI: 10.5853/jos.2024.03055
Wei Li, Mohamed F Doheim, Zhongming Qiu, Tan Wang, Zhibin Chen, Wenjie Zi, Qingwu Yang, Haitao Guan, Hongyu Qiao, Wenhua Liu, Wei Hu, Xinfeng Liu, Jinbo Huang, Zhongkui Han, Zhonglun Chen, Zhenqiang Zhao, Wen Sun, Raul G Nogueira

Background and purpose: Limited evidence exists on the effectiveness of endovascular treatment (EVT) for acute posterior circulation tandem lesion (PCTL). This study aimed to explore the role of extracranial vertebral artery (VA) stenting in patients with PCTL stroke undergoing EVT.

Methods: Individual patient data were pooled from the BASILAR (EVT for Acute Basilar Artery Occlusion Study) and PERSIST (Posterior Circulation Ischemic Stroke) registries. Patients with PCTLs who underwent EVT were included in the present cohort and divided into the stenting and nonstenting groups based on the placement of extracranial VA stents. The primary efficacy outcome was the modified Rankin Scale (mRS) scores at 90 days and 1 year. Safety outcomes included 24-hour symptomatic intracranial hemorrhage (sICH) and all-cause mortality at 90 days and 1 year post-surgery.

Results: A combined dataset of 1,320 patients with posterior circulation artery occlusion, including 263 (19.9%) with tandem lesions, of whom 217 (median age, 65 years; 82.9% male) met the inclusion criteria for the analysis. The stenting group had 84 (38.7%) patients, while the non-stenting group had 133 (61.3%). After adjustment for the potential confounders, extracranial VA stenting was associated with favorable shifts in mRS scores at both 90 days (adjusted common odds ratio [OR], 2.30; 95% confidence interval [CI], 1.23-4.28; P<0.01) and 1 year (adjusted OR [aOR], 2.04; 95% CI [1.05-3.97]; P=0.04), along with lower rate of mortality at both 90 days (aOR, 0.45; 95% CI [0.21-0.93]; P=0.01) and 1 year (aOR, 0.36; 95% CI [0.16-0.79]; P=0.01), with no significant difference in sICH incidence (aOR, 0.35; 95% CI [0.06-1.98]; P=0.24).

Conclusion: Extracranial VA stenting during EVT may improve functional outcomes and reduce mortality in patients with PCTL strokes.

背景与目的:血管内治疗(EVT)治疗急性后循环串联病变(PCTL)的有效性证据有限。本研究旨在探讨颅外椎动脉(VA)支架植入术在PCTL脑卒中行EVT患者中的作用。方法:将来自BASILAR(急性基底动脉闭塞研究EVT)和PERSIST(后循环缺血性卒中)登记的个体患者数据汇总。接受EVT的pctl患者被纳入本队列,并根据颅内外VA支架的放置情况分为支架置入术组和非支架置入术组。主要疗效指标为90天和1年时的改良Rankin量表(mRS)评分。安全性指标包括术后24小时症状性颅内出血(sICH)和术后90天和1年的全因死亡率。结果:合并数据集包括1320例后循环动脉闭塞患者,其中263例(19.9%)有串联病变,其中217例(中位年龄65岁;82.9%男性)符合分析纳入标准。支架组84例(38.7%),非支架组133例(61.3%)。在对潜在混杂因素进行调整后,颅外VA支架植入与90天mRS评分的有利变化相关(调整后的常见优势比[OR], 2.30;95%置信区间[CI], 1.23-4.28;结论:EVT期间颅内外VA支架术可改善PCTL脑卒中患者的功能结局并降低死亡率。
{"title":"Endovascular Treatment for Acute Posterior Circulation Tandem Lesions: Insights From the BASILAR and PERSIST Registries.","authors":"Wei Li, Mohamed F Doheim, Zhongming Qiu, Tan Wang, Zhibin Chen, Wenjie Zi, Qingwu Yang, Haitao Guan, Hongyu Qiao, Wenhua Liu, Wei Hu, Xinfeng Liu, Jinbo Huang, Zhongkui Han, Zhonglun Chen, Zhenqiang Zhao, Wen Sun, Raul G Nogueira","doi":"10.5853/jos.2024.03055","DOIUrl":"10.5853/jos.2024.03055","url":null,"abstract":"<p><strong>Background and purpose: </strong>Limited evidence exists on the effectiveness of endovascular treatment (EVT) for acute posterior circulation tandem lesion (PCTL). This study aimed to explore the role of extracranial vertebral artery (VA) stenting in patients with PCTL stroke undergoing EVT.</p><p><strong>Methods: </strong>Individual patient data were pooled from the BASILAR (EVT for Acute Basilar Artery Occlusion Study) and PERSIST (Posterior Circulation Ischemic Stroke) registries. Patients with PCTLs who underwent EVT were included in the present cohort and divided into the stenting and nonstenting groups based on the placement of extracranial VA stents. The primary efficacy outcome was the modified Rankin Scale (mRS) scores at 90 days and 1 year. Safety outcomes included 24-hour symptomatic intracranial hemorrhage (sICH) and all-cause mortality at 90 days and 1 year post-surgery.</p><p><strong>Results: </strong>A combined dataset of 1,320 patients with posterior circulation artery occlusion, including 263 (19.9%) with tandem lesions, of whom 217 (median age, 65 years; 82.9% male) met the inclusion criteria for the analysis. The stenting group had 84 (38.7%) patients, while the non-stenting group had 133 (61.3%). After adjustment for the potential confounders, extracranial VA stenting was associated with favorable shifts in mRS scores at both 90 days (adjusted common odds ratio [OR], 2.30; 95% confidence interval [CI], 1.23-4.28; P<0.01) and 1 year (adjusted OR [aOR], 2.04; 95% CI [1.05-3.97]; P=0.04), along with lower rate of mortality at both 90 days (aOR, 0.45; 95% CI [0.21-0.93]; P=0.01) and 1 year (aOR, 0.36; 95% CI [0.16-0.79]; P=0.01), with no significant difference in sICH incidence (aOR, 0.35; 95% CI [0.06-1.98]; P=0.24).</p><p><strong>Conclusion: </strong>Extracranial VA stenting during EVT may improve functional outcomes and reduce mortality in patients with PCTL strokes.</p>","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"27 1","pages":"75-84"},"PeriodicalIF":6.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Onset-to-Door Time on Endovascular Therapy for Basilar Artery Occlusion. 起病至开门时间对基底动脉闭塞血管内治疗的影响。
IF 6 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-31 DOI: 10.5853/jos.2024.03874
Tianlong Liu, Chunrong Tao, Zhongjun Chen, Lihua Xu, Yuyou Zhu, Rui Li, Jun Sun, Li Wang, Chao Zhang, Jianlong Song, Xiaozhong Jing, Adnan I Qureshi, Mohamad Abdalkader, Thanh N Nguyen, Raul G Nogueira, Jeffrey L Saver, Wei Hu
{"title":"Impact of Onset-to-Door Time on Endovascular Therapy for Basilar Artery Occlusion.","authors":"Tianlong Liu, Chunrong Tao, Zhongjun Chen, Lihua Xu, Yuyou Zhu, Rui Li, Jun Sun, Li Wang, Chao Zhang, Jianlong Song, Xiaozhong Jing, Adnan I Qureshi, Mohamad Abdalkader, Thanh N Nguyen, Raul G Nogueira, Jeffrey L Saver, Wei Hu","doi":"10.5853/jos.2024.03874","DOIUrl":"10.5853/jos.2024.03874","url":null,"abstract":"","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"27 1","pages":"140-143"},"PeriodicalIF":6.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive Modeling of Symptomatic Intracranial Hemorrhage Following Endovascular Thrombectomy: Insights From the Nationwide TREAT-AIS Registry. 血管内取栓后症状性颅内出血的预测模型:来自全国treatment - ais注册的见解。
IF 6 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-31 DOI: 10.5853/jos.2024.04119
Jia-Hung Chen, I-Chang Su, Yueh-Hsun Lu, Yi-Chen Hsieh, Chih-Hao Chen, Chun-Jen Lin, Yu-Wei Chen, Kuan-Hung Lin, Pi-Shan Sung, Chih-Wei Tang, Hai-Jui Chu, Chuan-Hsiu Fu, Chao-Liang Chou, Cheng-Yu Wei, Shang-Yih Yan, Po-Lin Chen, Hsu-Ling Yeh, Sheng-Feng Sung, Hon-Man Liu, Ching-Huang Lin, Meng Lee, Sung-Chun Tang, I-Hui Lee, Lung Chan, Li-Ming Lien, Hung-Yi Chiou, Jiunn-Tay Lee, Jiann-Shing Jeng

Background and purpose: Symptomatic intracranial hemorrhage (sICH) following endovascular thrombectomy (EVT) is a severe complication associated with adverse functional outcomes and increased mortality rates. Currently, a reliable predictive model for sICH risk after EVT is lacking.

Methods: This study used data from patients aged ≥20 years who underwent EVT for anterior circulation stroke from the nationwide Taiwan Registry of Endovascular Thrombectomy for Acute Ischemic Stroke (TREAT-AIS). A predictive model including factors associated with an increased risk of sICH after EVT was developed to differentiate between patients with and without sICH. This model was compared existing predictive models using nationwide registry data to evaluate its relative performance.

Results: Of the 2,507 identified patients, 158 developed sICH after EVT. Factors such as diastolic blood pressure, Alberta Stroke Program Early CT Score, platelet count, glucose level, collateral score, and successful reperfusion were associated with the risk of sICH after EVT. The TREAT-AIS score demonstrated acceptable predictive accuracy (area under the curve [AUC]=0.694), with higher scores being associated with an increased risk of sICH (odds ratio=2.01 per score increase, 95% confidence interval=1.64-2.45, P<0.001). The discriminatory capacity of the score was similar in patients with symptom onset beyond 6 hours (AUC=0.705). Compared to existing models, the TREAT-AIS score consistently exhibited superior predictive accuracy, although this difference was marginal.

Conclusion: s The TREAT-AIS score outperformed existing models, and demonstrated an acceptable discriminatory capacity for distinguishing patients according to sICH risk levels. However, the differences between models were only marginal. Further research incorporating periprocedural and postprocedural factors is required to improve the predictive accuracy.

背景和目的:血管内血栓切除术(EVT)后的症状性颅内出血(siich)是一种严重的并发症,与不良功能结局和死亡率增加相关。目前,缺乏可靠的EVT术后siich风险预测模型。方法:本研究使用台湾省急性缺血性卒中血管内取栓登记(treatment - ais)中年龄≥20岁的前循环卒中EVT患者的数据。建立了一个预测模型,包括与EVT后sICH风险增加相关的因素,以区分有和没有sICH的患者。利用全国注册表数据对现有预测模型进行比较,评价模型的相对性能。结果:2507例确诊患者中,158例在EVT后发生sICH。舒张压、阿尔伯塔卒中计划早期CT评分、血小板计数、血糖水平、侧支评分和再灌注成功等因素与EVT后siich的风险相关。TREAT-AIS评分具有可接受的预测准确性(曲线下面积[AUC]=0.694),得分越高,siich风险越高(每得分增加的优势比=2.01,95%可信区间=1.64-2.45)。结论:5 TREAT-AIS评分优于现有模型,在根据siich风险水平区分患者方面具有可接受的区分能力。然而,模型之间的差异只是微乎其微。需要进一步研究纳入围手术期和术后因素,以提高预测的准确性。
{"title":"Predictive Modeling of Symptomatic Intracranial Hemorrhage Following Endovascular Thrombectomy: Insights From the Nationwide TREAT-AIS Registry.","authors":"Jia-Hung Chen, I-Chang Su, Yueh-Hsun Lu, Yi-Chen Hsieh, Chih-Hao Chen, Chun-Jen Lin, Yu-Wei Chen, Kuan-Hung Lin, Pi-Shan Sung, Chih-Wei Tang, Hai-Jui Chu, Chuan-Hsiu Fu, Chao-Liang Chou, Cheng-Yu Wei, Shang-Yih Yan, Po-Lin Chen, Hsu-Ling Yeh, Sheng-Feng Sung, Hon-Man Liu, Ching-Huang Lin, Meng Lee, Sung-Chun Tang, I-Hui Lee, Lung Chan, Li-Ming Lien, Hung-Yi Chiou, Jiunn-Tay Lee, Jiann-Shing Jeng","doi":"10.5853/jos.2024.04119","DOIUrl":"10.5853/jos.2024.04119","url":null,"abstract":"<p><strong>Background and purpose: </strong>Symptomatic intracranial hemorrhage (sICH) following endovascular thrombectomy (EVT) is a severe complication associated with adverse functional outcomes and increased mortality rates. Currently, a reliable predictive model for sICH risk after EVT is lacking.</p><p><strong>Methods: </strong>This study used data from patients aged ≥20 years who underwent EVT for anterior circulation stroke from the nationwide Taiwan Registry of Endovascular Thrombectomy for Acute Ischemic Stroke (TREAT-AIS). A predictive model including factors associated with an increased risk of sICH after EVT was developed to differentiate between patients with and without sICH. This model was compared existing predictive models using nationwide registry data to evaluate its relative performance.</p><p><strong>Results: </strong>Of the 2,507 identified patients, 158 developed sICH after EVT. Factors such as diastolic blood pressure, Alberta Stroke Program Early CT Score, platelet count, glucose level, collateral score, and successful reperfusion were associated with the risk of sICH after EVT. The TREAT-AIS score demonstrated acceptable predictive accuracy (area under the curve [AUC]=0.694), with higher scores being associated with an increased risk of sICH (odds ratio=2.01 per score increase, 95% confidence interval=1.64-2.45, P<0.001). The discriminatory capacity of the score was similar in patients with symptom onset beyond 6 hours (AUC=0.705). Compared to existing models, the TREAT-AIS score consistently exhibited superior predictive accuracy, although this difference was marginal.</p><p><strong>Conclusion: </strong>s The TREAT-AIS score outperformed existing models, and demonstrated an acceptable discriminatory capacity for distinguishing patients according to sICH risk levels. However, the differences between models were only marginal. Further research incorporating periprocedural and postprocedural factors is required to improve the predictive accuracy.</p>","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"27 1","pages":"85-94"},"PeriodicalIF":6.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reinforcement of Transdural Angiogenesis: A Novel Approach to Treating Ischemic Stroke With Cerebral Perfusion Impairment. 强化硬膜血管生成:一种治疗缺血性脑卒中伴脑灌注损伤的新方法。
IF 6 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-31 DOI: 10.5853/jos.2024.02810
Ji Man Hong, Hee Sun Shin

Cerebral hypoperfusion plays a critical role in early neurological deterioration and long-term outcomes in patients with acute ischemic stroke, which remains a major global health challenge. This review explored transdural angiogenesis as a promising therapeutic strategy to restore cerebral perfusion in patients with ischemic stroke. The multiple burr hole procedure has been preliminarily used as an indirect revascularization method to induce transdural arteriogenesis. Theoretically, its efficacy could be enhanced by combining it with angiogenic boosters, such as erythropoietin. Recent clinical and preclinical studies have revealed that this combination therapy promotes angiogenesis and arteriogenesis, leading to successful revascularization across the dura mater and improved cerebral blood flow. This strategy may be particularly beneficial for high-risk patients with recurrent ischemic events, such as those with moyamoya disease or intracranial arterial occlusion, representing an effective strategy when conventional medical treatments are insufficient. This review highlights the potential of transdural angiogenesis enhancement as a novel intervention for ischemic stroke, offering an alternative to thrombolysis or endovascular treatment, particularly in acute stroke patients with impaired cerebral perfusion. This approach has the potential to bridge the treatment gap for patients outside the therapeutic window for acute stroke interventions. Although further research is required to refine this technique and validate its efficacy in broader clinical settings, early results have revealed promising outcomes at reducing stroke-related complications and improving patient prognosis. This review indicates that this novel strategy may offer hope for managing ischemic stroke and related conditions associated with significant cerebral hypoperfusion.

脑灌注不足在急性缺血性卒中患者的早期神经功能恶化和长期预后中起着关键作用,这仍然是一项重大的全球健康挑战。这篇综述探讨了经硬膜血管生成作为恢复缺血性脑卒中患者脑灌注的一种有前景的治疗策略。多钻孔术已初步作为间接血运重建方法用于诱导硬膜外动脉形成。从理论上讲,它的功效可以通过与促红细胞生成素等血管生成助推器结合而增强。最近的临床和临床前研究表明,这种联合治疗促进血管生成和动脉生成,导致成功的跨硬脑膜血运重建和改善脑血流量。这种策略可能对复发性缺血性事件的高风险患者特别有益,例如烟雾病或颅内动脉闭塞患者,在常规医学治疗不足时是一种有效的策略。这篇综述强调了硬膜血管生成增强作为缺血性卒中的一种新的干预手段的潜力,提供了一种替代溶栓或血管内治疗的方法,特别是在脑灌注受损的急性卒中患者中。这种方法有可能弥补急性卒中干预治疗窗口外患者的治疗缺口。虽然需要进一步的研究来完善这项技术并验证其在更广泛的临床环境中的有效性,但早期的结果已经显示出在减少卒中相关并发症和改善患者预后方面有希望的结果。这一综述表明,这种新策略可能为管理缺血性卒中和与显著脑灌注不足相关的相关疾病提供希望。
{"title":"Reinforcement of Transdural Angiogenesis: A Novel Approach to Treating Ischemic Stroke With Cerebral Perfusion Impairment.","authors":"Ji Man Hong, Hee Sun Shin","doi":"10.5853/jos.2024.02810","DOIUrl":"10.5853/jos.2024.02810","url":null,"abstract":"<p><p>Cerebral hypoperfusion plays a critical role in early neurological deterioration and long-term outcomes in patients with acute ischemic stroke, which remains a major global health challenge. This review explored transdural angiogenesis as a promising therapeutic strategy to restore cerebral perfusion in patients with ischemic stroke. The multiple burr hole procedure has been preliminarily used as an indirect revascularization method to induce transdural arteriogenesis. Theoretically, its efficacy could be enhanced by combining it with angiogenic boosters, such as erythropoietin. Recent clinical and preclinical studies have revealed that this combination therapy promotes angiogenesis and arteriogenesis, leading to successful revascularization across the dura mater and improved cerebral blood flow. This strategy may be particularly beneficial for high-risk patients with recurrent ischemic events, such as those with moyamoya disease or intracranial arterial occlusion, representing an effective strategy when conventional medical treatments are insufficient. This review highlights the potential of transdural angiogenesis enhancement as a novel intervention for ischemic stroke, offering an alternative to thrombolysis or endovascular treatment, particularly in acute stroke patients with impaired cerebral perfusion. This approach has the potential to bridge the treatment gap for patients outside the therapeutic window for acute stroke interventions. Although further research is required to refine this technique and validate its efficacy in broader clinical settings, early results have revealed promising outcomes at reducing stroke-related complications and improving patient prognosis. This review indicates that this novel strategy may offer hope for managing ischemic stroke and related conditions associated with significant cerebral hypoperfusion.</p>","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"27 1","pages":"30-40"},"PeriodicalIF":6.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemorrhagic Complications Following Endovascular Treatment for Atherothrombotic Large Vessel Occlusion. 动脉粥样硬化性大血管闭塞的血管内治疗后出血并发症。
IF 6 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-31 DOI: 10.5853/jos.2024.01935
Satoru Fujiwara, Kazutaka Uchida, Tsuyoshi Ohta, Nobuyuki Ohara, Michi Kawamoto, Hiroshi Yamagami, Kazunori Toyoda, Yuji Matsumaru, Yasushi Matsumoto, Kenichi Todo, Mikito Hayakawa, Seigo Shindo, Shinzo Ota, Masafumi Morimoto, Masataka Takeuchi, Hirotoshi Imamura, Hiroyuki Ikeda, Kanta Tanaka, Hideyuki Ishihara, Hiroto Kakita, Takanori Sano, Hayato Araki, Tatsufumi Nomura, Mikiya Beppu, Fumihiro Sakakibara, Manabu Shirakawa, Shinichi Yoshimura, Nobuyuki Sakai
{"title":"Hemorrhagic Complications Following Endovascular Treatment for Atherothrombotic Large Vessel Occlusion.","authors":"Satoru Fujiwara, Kazutaka Uchida, Tsuyoshi Ohta, Nobuyuki Ohara, Michi Kawamoto, Hiroshi Yamagami, Kazunori Toyoda, Yuji Matsumaru, Yasushi Matsumoto, Kenichi Todo, Mikito Hayakawa, Seigo Shindo, Shinzo Ota, Masafumi Morimoto, Masataka Takeuchi, Hirotoshi Imamura, Hiroyuki Ikeda, Kanta Tanaka, Hideyuki Ishihara, Hiroto Kakita, Takanori Sano, Hayato Araki, Tatsufumi Nomura, Mikiya Beppu, Fumihiro Sakakibara, Manabu Shirakawa, Shinichi Yoshimura, Nobuyuki Sakai","doi":"10.5853/jos.2024.01935","DOIUrl":"10.5853/jos.2024.01935","url":null,"abstract":"","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"27 1","pages":"149-153"},"PeriodicalIF":6.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Hypertension and Subclinical Organ Damage With Mortality Due to Stroke and Its Subtypes. 高血压和亚临床器官损害与脑卒中及其亚型死亡率的关系。
IF 6 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-31 DOI: 10.5853/jos.2024.01683
Kenichi Ariyada, Kazumasa Yamagishi, Toshimi Sairenchi, Tomomi Kihara, Hiroyasu Iso, Fujiko Irie
{"title":"Association of Hypertension and Subclinical Organ Damage With Mortality Due to Stroke and Its Subtypes.","authors":"Kenichi Ariyada, Kazumasa Yamagishi, Toshimi Sairenchi, Tomomi Kihara, Hiroyasu Iso, Fujiko Irie","doi":"10.5853/jos.2024.01683","DOIUrl":"10.5853/jos.2024.01683","url":null,"abstract":"","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"27 1","pages":"144-148"},"PeriodicalIF":6.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Estimates of Reported Vaccine-Associated Ischemic Stroke for 1969-2023: A Comprehensive Analysis of the World Health Organization Global Pharmacovigilance Database. 1969-2023年全球疫苗相关缺血性中风报告估计数:世界卫生组织全球药物警戒数据库综合分析》。
IF 8.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-13 DOI: 10.5853/jos.2024.01536
Jaehyeong Cho,Jaeyu Park,Hyesu Jo,Yesol Yim,Ho Geol Woo,Jiyeon Oh,Dong Keon Yon
{"title":"Global Estimates of Reported Vaccine-Associated Ischemic Stroke for 1969-2023: A Comprehensive Analysis of the World Health Organization Global Pharmacovigilance Database.","authors":"Jaehyeong Cho,Jaeyu Park,Hyesu Jo,Yesol Yim,Ho Geol Woo,Jiyeon Oh,Dong Keon Yon","doi":"10.5853/jos.2024.01536","DOIUrl":"https://doi.org/10.5853/jos.2024.01536","url":null,"abstract":"","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"89 1","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethnic Differences in the Safety and Efficacy of Tenecteplase Versus Alteplase for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. 特奈普酶与阿替普酶治疗急性缺血性卒中的安全性和有效性的种族差异:系统回顾与元分析》。
IF 8.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-13 DOI: 10.5853/jos.2024.01284
Jin Hean Koh,Claire Yi Jia Lim,Lucas Tze Peng Tan,Ching-Hui Sia,Kian Keong Poh,Vijay Kumar Sharma,Leonard Leong Litt Yeo,Andrew Fu Wah Ho,Teddy Wu,William Kok-Fai Kong,Benjamin Yong Qiang Tan
Background and PurposeTenecteplase is a thrombolytic agent with pharmacological advantages over alteplase and has been shown to be noninferior to alteplase for acute ischemic stroke in randomized trials. However, evidence pertaining to the safety and efficacy of tenecteplase in patients from different ethnic groups is lacking. The aim of this systematic review and metaanalysis was to investigate ethnicity-specific differences in the safety and efficacy of tenecteplase versus alteplase in patients with acute ischemic stroke.MethodsFollowing an International Prospective Register of Systematic Reviews (PROSPERO)- registered protocol (CRD42023475038), three authors conducted a systematic review of the PubMed/MEDLINE, Embase, Cochrane Library, and CINAHL databases for articles comparing the use of tenecteplase with any thrombolytic agent in patients with acute ischemic stroke up to November 20, 2023. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Two independent authors extracted data onto a standardized data collection sheet. A pairwise meta-analysis was conducted in risk ratios (RR).ResultsFrom 34 studies (59,601 participants), the rate of complete recanalization was significantly higher (P<0.01) in Asian (RR: 1.91, 95% confidence interval [CI]: 1.30 to 2.80) versus Caucasian patients (RR: 0.99, 95% CI: 0.87 to 1.14). However, Asian patients (RR: 1.18, 95% CI: 0.87 to 1.62) had significantly higher (P=0.01) rates of mortality compared with Caucasian patients (RR: 1.10, 95% CI: 1.00 to 1.22). Caucasian patients were also more likely to attain a modified Rankin Scale (mRS) score of 0 to 2 at follow-up (RR: 1.14, 95% CI, 1.10 to 1.19) compared with Asian (RR: 1.00, 95% CI, 0.95 to 1.05) patients. There was no significant difference in the rate of symptomatic intracranial hemorrhage (P=0.20) and any intracranial hemorrhage (P=0.83) between Asian and Caucasian patients.ConclusionTenecteplase was associated with significantly higher rates of complete recanalization in Asian patients compared with Caucasian patients. However, tenecteplase was associated with higher rates of mortality and lower rates of mRS 0 to 2 in Asian patients compared with Caucasian patients. It may be beneficial to study the variations in response to tenecteplase among patients of different ethnic groups in large prospective cohort studies.
背景和目的替奈普酶是一种溶栓药物,与阿替普酶相比具有药理优势,在随机试验中显示其治疗急性缺血性卒中的效果不劣于阿替普酶。然而,有关替奈普酶在不同种族患者中的安全性和有效性的证据还很缺乏。本系统综述和荟萃分析旨在研究替奈普酶与阿替普酶在急性缺血性卒中患者中安全性和有效性的种族特异性差异。方法根据国际系统性综述前瞻性注册(PROSPERO)注册协议(CRD42023475038),三位作者对PubMed/MEDLINE、Embase、Cochrane Library和CINAHL数据库中截至2023年11月20日的文章进行了系统性综述,比较了在急性缺血性卒中患者中使用替奈普酶和任何溶栓药物的情况。采用建议评估、发展和评价分级(GRADE)框架对证据的确定性进行评估。两位独立作者在标准化数据收集表上提取数据。结果34项研究(59601名参与者)中,亚裔患者(RR:1.91,95%置信区间[CI]:1.30至2.80)的完全再通率显著高于白种人患者(RR:0.99,95%置信区间:0.87至1.14)(P<0.01)。然而,亚裔患者的死亡率(RR:1.18,95% CI:0.87 至 1.62)明显高于白种人患者(RR:1.10,95% CI:1.00 至 1.22)(P=0.01)。与亚裔患者(RR:1.00,95% CI:0.95 至 1.05)相比,白种人患者在随访时更有可能达到改良兰肯量表(mRS)0 至 2 分(RR:1.14,95% CI:1.10 至 1.19)。亚裔和白种人患者的症状性颅内出血率(P=0.20)和任何颅内出血率(P=0.83)无明显差异。然而,与白种人患者相比,替尼替普酶与亚裔患者较高的死亡率和较低的 mRS 0 至 2 相关。在大型前瞻性队列研究中研究不同种族患者对替奈普酶反应的差异可能会有所裨益。
{"title":"Ethnic Differences in the Safety and Efficacy of Tenecteplase Versus Alteplase for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.","authors":"Jin Hean Koh,Claire Yi Jia Lim,Lucas Tze Peng Tan,Ching-Hui Sia,Kian Keong Poh,Vijay Kumar Sharma,Leonard Leong Litt Yeo,Andrew Fu Wah Ho,Teddy Wu,William Kok-Fai Kong,Benjamin Yong Qiang Tan","doi":"10.5853/jos.2024.01284","DOIUrl":"https://doi.org/10.5853/jos.2024.01284","url":null,"abstract":"Background and PurposeTenecteplase is a thrombolytic agent with pharmacological advantages over alteplase and has been shown to be noninferior to alteplase for acute ischemic stroke in randomized trials. However, evidence pertaining to the safety and efficacy of tenecteplase in patients from different ethnic groups is lacking. The aim of this systematic review and metaanalysis was to investigate ethnicity-specific differences in the safety and efficacy of tenecteplase versus alteplase in patients with acute ischemic stroke.MethodsFollowing an International Prospective Register of Systematic Reviews (PROSPERO)- registered protocol (CRD42023475038), three authors conducted a systematic review of the PubMed/MEDLINE, Embase, Cochrane Library, and CINAHL databases for articles comparing the use of tenecteplase with any thrombolytic agent in patients with acute ischemic stroke up to November 20, 2023. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Two independent authors extracted data onto a standardized data collection sheet. A pairwise meta-analysis was conducted in risk ratios (RR).ResultsFrom 34 studies (59,601 participants), the rate of complete recanalization was significantly higher (P<0.01) in Asian (RR: 1.91, 95% confidence interval [CI]: 1.30 to 2.80) versus Caucasian patients (RR: 0.99, 95% CI: 0.87 to 1.14). However, Asian patients (RR: 1.18, 95% CI: 0.87 to 1.62) had significantly higher (P=0.01) rates of mortality compared with Caucasian patients (RR: 1.10, 95% CI: 1.00 to 1.22). Caucasian patients were also more likely to attain a modified Rankin Scale (mRS) score of 0 to 2 at follow-up (RR: 1.14, 95% CI, 1.10 to 1.19) compared with Asian (RR: 1.00, 95% CI, 0.95 to 1.05) patients. There was no significant difference in the rate of symptomatic intracranial hemorrhage (P=0.20) and any intracranial hemorrhage (P=0.83) between Asian and Caucasian patients.ConclusionTenecteplase was associated with significantly higher rates of complete recanalization in Asian patients compared with Caucasian patients. However, tenecteplase was associated with higher rates of mortality and lower rates of mRS 0 to 2 in Asian patients compared with Caucasian patients. It may be beneficial to study the variations in response to tenecteplase among patients of different ethnic groups in large prospective cohort studies.","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"32 1","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142269749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inpatient Outcomes of Cerebral Venous Thrombosis in Patients With Malignancy Throughout the United States. 全美恶性肿瘤患者脑静脉血栓的住院治疗结果。
IF 8.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-13 DOI: 10.5853/jos.2023.04098
Sima Vazqez,Ankita Das,Eris Spirollari,Paige Brabant,Bridget Nolan,Kevin Clare,Jose F Dominguez,Neha Dangayach,Krishna Amuluru,Shadi Yaghi,Ji Chong,Chaitanya Medicherla,Halla Nuoaman,Neisha Patel,Stephan A Mayer,Chirag D Gandhi,Fawaz Al-Mufti
Background and PurposeCerebral venous thrombosis (CVT) is associated with a high degree of morbidity and mortality. Our objective is to elucidate characteristics, treatments, and outcomes of patients with cancer and CVT (CA-CVT).MethodsThe 2016-2019 National Inpatient Sample (NIS) database was queried for patients with a primary diagnosis of CVT. Patients with a currently active diagnosis of malignancy (CA-CVT) were then identified. Demographics and comorbidities were compared between CA-CVT and CVT patients. Subgroup analyses explored patients with hematopoietic cancer and non-hematopoietic cancers. Stroke severity and treatment were explored. Inpatient outcomes studied were discharge disposition, length of stay, and mortality.ResultsBetween 2016 and 2019, 6,140 patients had a primary diagnosis code of CVT, and 370 (6.0%) patients had a coexisting malignancy. The most common malignancy was hematopoietic (n=195, 52.7%), followed by central nervous system (n=40, 10.8%), respiratory (n=40, 10.8%), and breast (n=40, 10.8%). These patients tended to be older than non-CA-CVT and were more likely to have coexisting comorbidities. CA-CVT patients had higher severity scores on the International Study of Cerebral Vein and Dural Sinus Thrombosis Risk Score (ISCVT-RS) and increased complications. In a propensity-score matched cohort, there were no differences in inpatient outcomes.ConclusionMalignancy occurs in 6% of patients presenting with CVT and should be considered a potential comorbidity in instances where clear causes of hypercoagulabilty have not been identified. Malignancy was linked to higher mortality rates. Nonetheless, after adjusting for the severity of CVT, the outcomes for inpatients with cancer-associated CVT were comparable to those without cancer, indicating that the increased mortality associated with malignancy is probably due to more severe CVT conditions.
背景和目的脑静脉血栓(CVT)与高发病率和高死亡率相关。我们的目的是阐明癌症合并 CVT(CA-CVT)患者的特征、治疗方法和预后。方法查询 2016-2019 年全国住院患者样本(NIS)数据库,寻找主要诊断为 CVT 的患者。然后确定了目前正在进行恶性肿瘤诊断(CA-CVT)的患者。比较了 CA-CVT 和 CVT 患者的人口统计学特征和合并症。对造血癌症和非造血癌症患者进行了分组分析。研究还探讨了中风的严重程度和治疗方法。研究的住院结果包括出院处置、住院时间和死亡率。结果2016年至2019年间,6140名患者的主要诊断代码为CVT,370名(6.0%)患者合并有恶性肿瘤。最常见的恶性肿瘤是造血系统恶性肿瘤(195人,占52.7%),其次是中枢神经系统恶性肿瘤(40人,占10.8%)、呼吸系统恶性肿瘤(40人,占10.8%)和乳腺恶性肿瘤(40人,占10.8%)。这些患者的年龄往往比非CA-CVT患者大,而且更有可能合并其他疾病。CA-CVT患者在脑静脉和硬脑膜窦血栓形成国际研究风险评分(ISCVT-RS)中的严重程度得分更高,并发症也更多。在倾向分数匹配队列中,住院患者的预后没有差异。结论6%的CVT患者患有恶性肿瘤,在高凝血功能障碍的病因尚未明确的情况下,恶性肿瘤应被视为一种潜在的合并症。恶性肿瘤与较高的死亡率有关。尽管如此,在对 CVT 的严重程度进行调整后,癌症相关 CVT 住院患者的预后与非癌症患者相当,这表明恶性肿瘤导致的死亡率升高可能是由于 CVT 病情更为严重所致。
{"title":"Inpatient Outcomes of Cerebral Venous Thrombosis in Patients With Malignancy Throughout the United States.","authors":"Sima Vazqez,Ankita Das,Eris Spirollari,Paige Brabant,Bridget Nolan,Kevin Clare,Jose F Dominguez,Neha Dangayach,Krishna Amuluru,Shadi Yaghi,Ji Chong,Chaitanya Medicherla,Halla Nuoaman,Neisha Patel,Stephan A Mayer,Chirag D Gandhi,Fawaz Al-Mufti","doi":"10.5853/jos.2023.04098","DOIUrl":"https://doi.org/10.5853/jos.2023.04098","url":null,"abstract":"Background and PurposeCerebral venous thrombosis (CVT) is associated with a high degree of morbidity and mortality. Our objective is to elucidate characteristics, treatments, and outcomes of patients with cancer and CVT (CA-CVT).MethodsThe 2016-2019 National Inpatient Sample (NIS) database was queried for patients with a primary diagnosis of CVT. Patients with a currently active diagnosis of malignancy (CA-CVT) were then identified. Demographics and comorbidities were compared between CA-CVT and CVT patients. Subgroup analyses explored patients with hematopoietic cancer and non-hematopoietic cancers. Stroke severity and treatment were explored. Inpatient outcomes studied were discharge disposition, length of stay, and mortality.ResultsBetween 2016 and 2019, 6,140 patients had a primary diagnosis code of CVT, and 370 (6.0%) patients had a coexisting malignancy. The most common malignancy was hematopoietic (n=195, 52.7%), followed by central nervous system (n=40, 10.8%), respiratory (n=40, 10.8%), and breast (n=40, 10.8%). These patients tended to be older than non-CA-CVT and were more likely to have coexisting comorbidities. CA-CVT patients had higher severity scores on the International Study of Cerebral Vein and Dural Sinus Thrombosis Risk Score (ISCVT-RS) and increased complications. In a propensity-score matched cohort, there were no differences in inpatient outcomes.ConclusionMalignancy occurs in 6% of patients presenting with CVT and should be considered a potential comorbidity in instances where clear causes of hypercoagulabilty have not been identified. Malignancy was linked to higher mortality rates. Nonetheless, after adjusting for the severity of CVT, the outcomes for inpatients with cancer-associated CVT were comparable to those without cancer, indicating that the increased mortality associated with malignancy is probably due to more severe CVT conditions.","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"30 1","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanical Thrombectomy Versus Intravenous Thrombolysis in Distal Medium Vessel Acute Ischemic Stroke: A Multinational Multicenter Propensity Score-Matched Study. 机械取栓术与静脉溶栓治疗远端中血管急性缺血性卒中:一项跨国多中心倾向评分匹配研究。
IF 8.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-13 DOI: 10.5853/jos.2024.01389
Hamza Adel Salim,Vivek Yedavalli,Basel Musmar,Nimer Adeeb,Muhammed Amir Essibayi,Kareem El Naamani,Nils Henninger,Sri Hari Sundararajan,Anna Luisa Kühn,Jane Khalife,Sherief Ghozy,Luca Scarcia,Benjamin Y Q Tan,Benjamin Pulli,Jeremy J Heit,Robert W Regenhardt,Nicole M Cancelliere,Joshua D Bernstock,Aymeric Rouchaud,Jens Fiehler,Sunil Sheth,Ajit S Puri,Christian Dyzmann,Marco Colasurdo,Xavier Barreau,Leonardo Renieri,João Pedro Filipe,Pablo Harker,Razvan Alexandru Radu,Thomas R Marotta,Julian Spears,Takahiro Ota,Ashkan Mowla,Pascal Jabbour,Arundhati Biswas,Frédéric Clarençon,James E Siegler,Thanh N Nguyen,Ricardo Varela,Amanda Baker,David Altschul,Nestor R Gonzalez,Markus A Möhlenbruch,Vincent Costalat,Benjamin Gory,Christian Paul Stracke,Mohammad Ali Aziz-Sultan,Constantin Hecker,Hamza Shaikh,David S Liebeskind,Alessandro Pedicelli,Andrea M Alexandre,Illario Tancredi,Tobias D Faizy,Erwah Kalsoum,Boris Lubicz,Aman B Patel,Vitor Mendes Pereira,Adrien Guenego,Adam A Dmytriw,
Background and PurposeThe management of acute ischemic stroke (AIS) due to distal medium vessel occlusion (DMVO) remains uncertain, particularly in comparing the effectiveness of intravenous thrombolysis (IVT) plus mechanical thrombectomy (MT) versus IVT alone. This study aimed to evaluate the safety and efficacy in DMVO patients treated with either MT-IVT or IVT alone.MethodsThis multinational study analyzed data from 37 centers across North America, Asia, and Europe. Patients with AIS due to DMVO were included, with data collected from September 2017 to July 2023. The primary outcome was functional independence, with secondary outcomes including mortality and safety measures such as types of intracerebral hemorrhage.ResultsThe study involved 1,057 patients before matching, and 640 patients post-matching. Functional outcomes at 90 days showed no significant difference between groups in achieving good functional recovery (modified Rankin Scale 0-1 and 0-2), with adjusted odds ratios (OR) of 1.21 (95% confidence interval [CI] 0.81 to 1.79; P=0.35) and 1.00 (95% CI 0.66 to 1.51; P>0.99), respectively. Mortality rates at 90 days were similar between the two groups (OR 0.75, 95% CI 0.44 to 1.29; P=0.30). The incidence of symptomatic intracerebral hemorrhage was comparable, but any type of intracranial hemorrhage was significantly higher in the MT-IVT group (OR 0.43, 95% CI 0.29 to 0.63; P<0.001).ConclusionThe results of this study indicate that while MT-IVT and IVT alone show similar functional and mortality outcomes in DMVO patients, MT-IVT presents a higher risk of hemorrhagic complications, thus MT-IVT may not routinely offer additional benefits over IVT alone for all DMVO stroke patients. Further prospective randomized trials are needed to identify patient subgroups most likely to benefit from MT-IVT treatment in DMVO.
背景和目的对远端中血管闭塞(DMVO)引起的急性缺血性卒中(AIS)的处理仍不确定,尤其是在比较静脉溶栓(IVT)加机械取栓(MT)与单纯 IVT 的有效性方面。这项研究旨在评估接受 MT-IVT 或单独 IVT 治疗的 DMVO 患者的安全性和有效性。研究纳入了因DMVO导致的AIS患者,数据收集时间为2017年9月至2023年7月。主要结果是功能独立性,次要结果包括死亡率和脑出血类型等安全性指标。90天后的功能结果显示,两组患者在实现良好功能恢复(改良Rankin量表0-1和0-2)方面无显著差异,调整后的几率比(OR)分别为1.21(95% 置信区间[CI] 0.81至1.79;P=0.35)和1.00(95% CI 0.66至1.51;P>0.99)。两组 90 天的死亡率相似(OR 0.75,95% CI 0.44 至 1.29;P=0.30)。无症状性脑出血的发生率相当,但任何类型的颅内出血在MT-IVT组明显较高(OR为0.43,95% CI为0.29至0.63;P<0.001)。结论本研究结果表明,虽然 MT-IVT 和单纯 IVT 在 DMVO 患者中显示出相似的功能和死亡率结果,但 MT-IVT 出血性并发症的风险更高,因此 MT-IVT 不一定能为所有 DMVO 卒中患者带来比单纯 IVT 更多的获益。需要进一步开展前瞻性随机试验,以确定 DMVO 患者中最有可能从 MT-IVT 治疗中获益的患者亚群。
{"title":"Mechanical Thrombectomy Versus Intravenous Thrombolysis in Distal Medium Vessel Acute Ischemic Stroke: A Multinational Multicenter Propensity Score-Matched Study.","authors":"Hamza Adel Salim,Vivek Yedavalli,Basel Musmar,Nimer Adeeb,Muhammed Amir Essibayi,Kareem El Naamani,Nils Henninger,Sri Hari Sundararajan,Anna Luisa Kühn,Jane Khalife,Sherief Ghozy,Luca Scarcia,Benjamin Y Q Tan,Benjamin Pulli,Jeremy J Heit,Robert W Regenhardt,Nicole M Cancelliere,Joshua D Bernstock,Aymeric Rouchaud,Jens Fiehler,Sunil Sheth,Ajit S Puri,Christian Dyzmann,Marco Colasurdo,Xavier Barreau,Leonardo Renieri,João Pedro Filipe,Pablo Harker,Razvan Alexandru Radu,Thomas R Marotta,Julian Spears,Takahiro Ota,Ashkan Mowla,Pascal Jabbour,Arundhati Biswas,Frédéric Clarençon,James E Siegler,Thanh N Nguyen,Ricardo Varela,Amanda Baker,David Altschul,Nestor R Gonzalez,Markus A Möhlenbruch,Vincent Costalat,Benjamin Gory,Christian Paul Stracke,Mohammad Ali Aziz-Sultan,Constantin Hecker,Hamza Shaikh,David S Liebeskind,Alessandro Pedicelli,Andrea M Alexandre,Illario Tancredi,Tobias D Faizy,Erwah Kalsoum,Boris Lubicz,Aman B Patel,Vitor Mendes Pereira,Adrien Guenego,Adam A Dmytriw,","doi":"10.5853/jos.2024.01389","DOIUrl":"https://doi.org/10.5853/jos.2024.01389","url":null,"abstract":"Background and PurposeThe management of acute ischemic stroke (AIS) due to distal medium vessel occlusion (DMVO) remains uncertain, particularly in comparing the effectiveness of intravenous thrombolysis (IVT) plus mechanical thrombectomy (MT) versus IVT alone. This study aimed to evaluate the safety and efficacy in DMVO patients treated with either MT-IVT or IVT alone.MethodsThis multinational study analyzed data from 37 centers across North America, Asia, and Europe. Patients with AIS due to DMVO were included, with data collected from September 2017 to July 2023. The primary outcome was functional independence, with secondary outcomes including mortality and safety measures such as types of intracerebral hemorrhage.ResultsThe study involved 1,057 patients before matching, and 640 patients post-matching. Functional outcomes at 90 days showed no significant difference between groups in achieving good functional recovery (modified Rankin Scale 0-1 and 0-2), with adjusted odds ratios (OR) of 1.21 (95% confidence interval [CI] 0.81 to 1.79; P=0.35) and 1.00 (95% CI 0.66 to 1.51; P>0.99), respectively. Mortality rates at 90 days were similar between the two groups (OR 0.75, 95% CI 0.44 to 1.29; P=0.30). The incidence of symptomatic intracerebral hemorrhage was comparable, but any type of intracranial hemorrhage was significantly higher in the MT-IVT group (OR 0.43, 95% CI 0.29 to 0.63; P<0.001).ConclusionThe results of this study indicate that while MT-IVT and IVT alone show similar functional and mortality outcomes in DMVO patients, MT-IVT presents a higher risk of hemorrhagic complications, thus MT-IVT may not routinely offer additional benefits over IVT alone for all DMVO stroke patients. Further prospective randomized trials are needed to identify patient subgroups most likely to benefit from MT-IVT treatment in DMVO.","PeriodicalId":17135,"journal":{"name":"Journal of Stroke","volume":"6 1","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Stroke
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1